scholarly journals Histological surprise, mammary analogue secretory carcinoma of parotid gland

2021 ◽  
Vol 8 (12) ◽  
pp. 3731
Author(s):  
Iram T. Pasha ◽  
Akhila K. ◽  
Ravikumar V. ◽  
Sandeep Kumar

A recent described entity, mammary analogue secretary carcinoma (MASC) in 2010 by Skalova et al whose morphological and immunohistochemical features are similar in secretory carcinoma of the breast and salivary gland. This is a low-grade carcinoma which presents as a firm, slow-growing, circumscribed lesion with male preponderance. We present a case report of MASC.

Author(s):  
Shashikant Anil Pol ◽  
Surinder K. Singhal ◽  
Nitin Gupta ◽  
Himanshu Bayad

<p>Mammary analogue secretary carcinoma are salivary gland tumors similar to secretary carcinoma of breast histologically. It usually affects adults with mean age group of 45 years. Clinically it is usually slow growing, low grade malignancy with favorable prognosis. We are reporting a case of 47 years old female presented with complaints of swelling behind left ear for last 7 years. It was slow growing, painless and persistent. On examination, 4 x 3 cm swelling was present just below left ear lobule. It was nontender, firm, irregular in shape with smooth surface with slight mobility and overlying skin pinchable. Fine needle aspiration cytology suggested benign tumor with cystic change. On contrast enhanced computed tomography scan, there was a lobulated hypodense lesion measuring 24×35×32 mm with internal septations and enhancement of wall in expected location of superficial as well as deep lobe of left parotid gland. Patient underwent left total conservative parotidectomy and histopathology came out to be secretory analogue mammary carcinoma. Subsequently she received post-operative radiotherapy. Patient is on regular follow up and disease free till date. Usually mammary analogue secretory carcinoma is a low-grade malignancy with good prognosis. Immunohistochemistry is confirmatory which shows positivity for S-100 protein and mammaglobin.</p>


Pathology ◽  
2017 ◽  
Vol 49 ◽  
pp. S92
Author(s):  
Wai Yun Woo ◽  
Rosemary Sutton ◽  
Asiri Arachchi ◽  
Sumeet Singh ◽  
Midhat Ghali

2021 ◽  
Author(s):  
Hongping Tang ◽  
Lihua Zhong ◽  
Hongbing Jiang ◽  
Gui’e Xie

Abstract Background: Secretory carcinoma of the breast is one of the rarest entities accounting for less than 0.15% of all infiltrating breast carcinomas. It has characteristic histopathological and molecular features and more favorable prognosis. In this case report, we describe a local advanced secretory carcinoma of the breast with chemo-resisted for neoadjuvant chemotherapy and unfavorable prognosis.Case Presentation: A hard, painless and palpably bossed mass about 12 cm in diameter occupied most of the left breast of a 39-year-old woman and fixation to the overlying skin. Breast ultrasonography and magnetic resonance imaging (MRI) scan gave the same grading as BI-RADS IV. A needle biopsy was performed and pathological diagnosis was secretory carcinoma. Neoadjuvant chemotherapy (NAC) was then performed, after which ultrasonography and MRI scan revealed the tumor was partial response for EC therapy while progressive disease after the DC therapy. The tumor showed chemo-resisted for neoadjuvant chemotherapy. Left breast mastectomy and axillary lymphadenectomy were subsequently performed. Tumor cells were triple-negative and positive for S-100 and periodic acid-Schiff (PAS) staining. Fluorescence in-situ hybridization (FISH) analysis indicated the fusion arrangement of ETV6-NTRK3 gene. The patient underwent multiple distant metastases in brain, and died of these metastases 19 months after initial diagnosis.Conclusion: Secretory carcinomas of breast have been described as a low-grade histologic subtype with a favorable prognosis. This case showed chemo-resisted for neoadjuvant chemotherapy, multiple distant metastases, and final an unfavorable prognosis. Further research is needed to better understanding of its behavior and treatment of this rare tumor.


2012 ◽  
Vol 2 (4) ◽  
pp. 331-334
Author(s):  
S Shrestha ◽  
CB Pun ◽  
R Basyal ◽  
T Pathak ◽  
S Bastola ◽  
...  

Polymorphous low-grade adenocarcinoma is a rare salivary gland malignant tumor of low aggressiveness, commonly occurring in minor salivary glands. Its origin in major salivary glands is considered exceedingly rare. We report a case of polymorphous low grade adenocarcinoma arising from left parotid in a 21-yearold female patient.Journal of Pathology of Nepal (2012) Vol. 2, 331-334DOI: http://dx.doi.org/10.3126/jpn.v2i4.6890


2017 ◽  
Vol 7 (26) ◽  
pp. 103-107
Author(s):  
Adelina Birceanu ◽  
Anca Evsei ◽  
Adrian Dumitru ◽  
Maria Sajin ◽  
Codrut Sarafoleanu

Abstract BACKGROUND. Primary malignant lymphomas of the salivary gland are rare, accounting for 2% of salivary gland tumors and 5% of all extranodal lymphomas. The clinical presentation is not particularly characteristic, a feature that usually leads to diagnostic and treatment delays. CASE REPORT. We report a case of a parotid gland triple-hit diffuse large B-cell (DLBCL) lymphoma associated with follicular lymphoma in a 76-year-old female patient with a unique personal history, which included a diagnosis of Sjogren Syndrome and exposure to a toxic working environment with pesticides. Diffuse large B-cell lymphomas are uncommon given the fact that most lymphoid malignancies are low-grade lymphomas, with MALT (mucosa associated lymphoid tissue) lymphomas being the most common. Triple-hit DLBCL are extremely rare and the diagnosis can be challenging. Parotidectomy, as the first step, must be followed by histopathology and immunohistochemistry for final diagnosis and treatment. CONCLUSION. This case highlights the fact that B-cell lymphoma in the salivary gland can be unrecognized due to unspecific symptoms and requires immunohistochemistry studies for confirmation. It is important to recognize triple-hit lymphoma due to its worse prognosis and differentiated treatment. Patients with Sjogren syndrome have additional risk factors for progression to lymphoma.


2017 ◽  
Vol 33 (2) ◽  
pp. 85-88 ◽  
Author(s):  
Sung Min Han ◽  
◽  
Sang Man Park ◽  
Hyeong Ju Kwon ◽  
Ji Hoon Kim ◽  
...  

Author(s):  
Meryem Doğan ◽  
Gözde Kır ◽  
Murat Hakan Karabulut ◽  
Ayşe Nur Ihvan

2020 ◽  
pp. 014556132095775
Author(s):  
Abdulkader Yassin-Kassab ◽  
Danielle Gainor ◽  
Ahmed Saeed Sufyan

Mammary analogue secretory carcinoma (MASC) of the salivary gland is a rare tumor that was first described by Skalova et al in 2010, and since then, only a few hundred cases have been reported in the literature. Prior to Skalova’s report, MASC was histologically misclassified as acinic cell carcinoma (ACC), pleomorphic adenoma, mucoepidermoid carcinoma, or adenocarcinoma, not otherwise specified. Mammary analogue secretory carcinoma has a low incidence rate overall, accounting for less than 0.3% of all salivary gland tumors. Histopathologic and cytogenic analysis of MASC is identical to secretory carcinoma of the breast, leading to the proposed name by Skalova. The purpose of this case presentation is to describe an atypical presentation of MASC, to compare this case with the classic description of MASC, and to contrast the various features of MASC to ACC in order to improve the accuracy of future diagnoses and help guide treatment.


Sign in / Sign up

Export Citation Format

Share Document